Gaiero David G 4
4 · Cyteir Therapeutics, Inc. · Filed Dec 14, 2023
Insider Transaction Report
Form 4
Gaiero David G
Vice President, Finance
Transactions
- Exercise/Conversion
Common Stock
2023-12-11$1.68/sh+1,620$2,722→ 89,660 total - Exercise/Conversion
Common Stock
2023-12-11$1.69/sh+2,373$4,010→ 92,033 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-11−1,620→ 19,435 totalExercise: $1.68Exp: 2030-12-10→ Common Stock (1,620 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-11−2,373→ 90,171 totalExercise: $1.69Exp: 2033-02-03→ Common Stock (2,373 underlying)
Footnotes (2)
- [F1]The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
- [F2]The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.